Thrive Capital Partners VII Growth, L.P.'s Form 4 filing
Oscar Health, Inc. (OSCR) · filed Nov 13, 2024
- Accession no.
- 0000950170-24-126662
- Filed
- Nov 13, 2024, 9:11 PM ET
- Trade date
- Nov 11-13, 2024
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Not checked
This filing lists 3 non-derivative transactions. Open-market purchases total $14.4M. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Thrive Capital Partners VII Growth, L.P.CIK 0001841736 | Director, 10% Owner |
| Claremount VII Associates, L.P.CIK 0001841808 | Director, 10% Owner |
| Thrive Partners VII GP, LLCCIK 0001877733 | Director, 10% Owner |
| Thrive Partners VII Growth GP, LLCCIK 0001877735 | Director, 10% Owner |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Nov 11, 2024 | Class A Common Stock | PPurchaseAcquired | +276,040 | $13.58F1 | +$3,748,043.52 | 5,031,262 | Indirect | |
| Nov 12, 2024 | Class A Common Stock | PPurchaseAcquired | +420,819 | $13.68F3 | +$5,755,625.63 | 5,452,081 | Indirect | |
| Nov 13, 2024 | Class A Common Stock | PPurchaseAcquired | +358,619 | $13.74F4 | +$4,926,313.34 | 5,810,700 | Indirect |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F1
Represents (i) 272,754 shares purchased by Thrive Capital Partners VII Growth, L.P. ("Thrive VII Growth") and (ii) 3,286 shares purchased by Claremount VII Associates, L.P. ("Claremount VII"). The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $13.205 to $13.92, inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price at which the transactions were effected. All shares were purchased in accordance with the daily volume and other limitations and requirements of Rule 10b-18. Following the reported transaction, 4,971,366 shares are held directly by Thrive VII Growth and 59,896 shares are held directly by Claremount VII.
Referenced by the price of 1 transaction in Table I.
- F3
Represents (i) 415,808 shares purchased by Thrive VII Growth and (ii) 5,011 shares purchased by Claremount VII. The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $13.45 to $14.29, inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price at which the transactions were effected. All shares were purchased in accordance with the daily volume and other limitations and requirements of Rule 10b-18. Following the reported transaction, 5,387,174 shares are held directly by Thrive VII Growth and 64,907 shares are held directly by Claremount VII.
Referenced by the price of 1 transaction in Table I.
- F4
Represents (i) 354,349 shares purchased by Thrive VII Growth and (ii) 4,270 shares purchased by Claremount VII. The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $13.435 to $14.21, inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price at which the transactions were effected. All shares were purchased in accordance with the daily volume and other limitations and requirements of Rule 10b-18. Following the reported transaction, 5,741,523 shares are held directly by Thrive VII Growth and 69,177shares are held directly by Claremount VII.
Referenced by the price of 1 transaction in Table I.
Remarks
Joshua Kushner has been deputized to represent the Reporting Persons on the board of directors of the Issuer. By virtue of Mr. Kushner's representation, for purposes of Section 16 of the Securities Exchange Act of 1934 (the "Exchange Act"), each of the Reporting Persons may be deemed directors by deputization of the Issuer. Mr. Kushner has filed a separate Section 16 report disclosing securities of the Issuer that he may be deemed to beneficially own for Section 16 purposes.